RGLS

Regulus Therapeutics Inc. Press Releases

$18.57
*  
1.13
6.48%
Get RGLS Alerts
*Delayed - data as of Nov. 26, 2014  -  Find a broker to begin trading RGLS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Endurance International Group Announces Completion of Public Offering
11/26/2014 4:05:00 PM - GlobeNewswire


Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference
11/26/2014 4:05:00 PM - PR Newswire


Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN''s Kidney Week 2014 Meeting
11/15/2014 6:00:00 PM - PR Newswire


Regulus to Present at the Credit Suisse Healthcare Conference
11/6/2014 4:05:00 PM - PR Newswire
▼-5.69 % Price Change since this news event. The Volume Ratio is 0.93.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Reports Third Quarter 2014 Financial Results and Recent Highlights
11/5/2014 4:05:00 PM - PR Newswire
▼-2.16 % Price Change since this news event. The Volume Ratio is 0.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters'' Option to Purchase Additional Shares
11/3/2014 4:05:00 PM - PR Newswire
▼-7.38 % Price Change since this news event. The Volume Ratio is 0.38.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
10/30/2014 4:05:00 PM - PR Newswire
▲1.87 % Price Change since this news event. The Volume Ratio is 0.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Announces Pricing of Public Offering of Common Stock
10/28/2014 8:10:00 PM - PR Newswire
▲6.24 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Announces Commencement of Public Offering of Common Stock
10/27/2014 4:00:00 PM - PR Newswire
▲2.09 % Price Change since this news event. The Volume Ratio is 0.41.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History
10/22/2014 7:30:00 AM - PR Newswire
▲174.30 % Price Change since this news event. The Volume Ratio is 302.28.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Presents New Preclinical Data on Multiple Programs and Provides Portfolio Overview at 10th Annual Oligonucleotide Therapeutics Society (OTS) Meeting
10/14/2014 8:00:00 AM - PR Newswire
▲181.36 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regulus Announces Notice of Allowance from U.S. Patent Office Related to microRNA-103/107 Program in Metabolic Disorders
9/24/2014 8:00:00 AM - PR Newswire


Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients
9/18/2014 8:00:00 AM - PR Newswire